Millennium Management’s Acurx Pharmaceuticals ACXP Stock Holding History

Millennium Management’s Portfolio ACXP Stock Details ACXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-41,427	Closed	-$103K	–	5639
2025 Q4	$103K	Buy	+41,427	New	+$199K	﹤0.01%	5630
2023 Q4	–	Sell	-729	Closed	-$20.8K	–	6020
2023 Q3	$20.8K	Sell	729 -136	-16%	-$5.2K	﹤0.01%	5644
2023 Q2	$45.9K	Sell	865 -238	-22%	-$14.2K	﹤0.01%	5491
2023 Q1	$76K	Sell	1,103 -352	-24%	-$25.7K	﹤0.01%	5506
2022 Q4	$116K	Sell	1,455 -914	-39%	-$60.1K	﹤0.01%	5530
2022 Q3	$142K	Buy	+2,369	New	+$177K	﹤0.01%	5831
2022 Q1	–	Sell	-697	Closed	-$61K	–	6831
2021 Q4	$61K	Sell	697 -808	-54%	-$76.9K	﹤0.01%	6421
2021 Q3	$155K	Buy	+1,505	New	+$155K	﹤0.01%	6232

Other funds holding ACXP

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

PFS

Prospect Financial Services Melville, New York $164M AUM 19.24% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

WIM

Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return

Millennium Management's ACXP Position: Q1 2026 in Review

Millennium Management sold out of Acurx Pharmaceuticals (ACXP) in Q1 2026, closing a stake of 41,427 shares — an estimated $103K sold.

Millennium Management first reported a position in ACXP in Q3 2021 and held it in 8 quarters. The position peaked at $155K in Q3 2021. 21 funds tracked by Wall St. Rank hold ACXP as of Q1 2026.

Millennium Management reported no remaining Acurx Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Millennium Management sold 41,427 Acurx Pharmaceuticals shares in Q1 2026, an estimated $103K.
Millennium Management first reported a position in Acurx Pharmaceuticals in Q3 2021 and held it in 8 quarters.
Millennium Management's Acurx Pharmaceuticals position peaked at $155K in Q3 2021.
21 funds tracked by Wall St. Rank held Acurx Pharmaceuticals as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.